Lantern Pharma (NAS: LTRN)

The AI engine Fit Assessment

Beta

Lantern Pharma, Inc. is a clinical stage pharmaceutical company focused on developing precision cancer drugs and revitalizing abandoned cancer therapies. They utilize advanced AI and machine learning techniques to enhance drug discovery and patient stratification in oncology.

Blurb

Lantern Pharma is a clinical stage biopharma company developing precision oncology therapies leveraging A.I., machine learning, and genomics

HQ Location

United States

Founded

2013

Employees

11 - 50

Total funding raised

$188.24M

Last Funding Event

Venture - Series Unknown, $60.00M, January 14, 2021

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.